Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity

Irene A. Abela^{1,25}, Chloé Pasin^{1,25}, Magdalena Schwarzmüller¹⁵, Selina Epp¹, Michèle E. Sickmann¹, Merle M. Schanz¹, Peter Rusert¹, Jacqueline Weber¹, Stefan Schmutz¹, Annette Audigé¹, Liridona Maliqi¹, Annika Hunziker¹, Maria C. Hesselman¹, Cyrille R. Niklaus¹, Jochen Gottschalk³, Eméry Schindler³, Alexander Wepf⁴, Urs Karrer⁵, Aline Wolfensberger², Silvana K. Rampini⁶, Patrick M. Meyer Sauteur⁷, Christoph Berger⁷, Michael Huber¹, Jürg Böni¹, Dominique L. Braun^{1,2}, Maddalena Marconato⁸, Markus G. Manz⁸, Beat M. Frey³, Huldrych F. Günthard^{1,2*}, Roger D. Kouyos^{1,2*}, Alexandra Trkola^{1*}

\$ these authors contributed equally

* these authors contributed equally

Affiliations

- ¹ Institute of Medical Virology, University of Zurich, Switzerland
- ² Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland
- ³ Blood Transfusion Service Zurich, Switzerland
- ⁴ Institute of Laboratory Medicine, Cantonal Hospital Winterthur, Switzerland
- ⁵ Department of Medicine, Cantonal Hospital Winterthur, Switzerland
- ⁶ Department of Internal Medicine, University Hospital Zurich, Switzerland
- ⁷ Division of Infectious Diseases and Hospital Epidemiology, University Children's Hospital Zurich, Switzerland
- ⁸ Department of Medical Oncology and Hematology, University Hospital and University of Zurich, Switzerland

Supplementary Fig. 1. Establishment of ABCORA seroprofiling. (a) Directed coupling of His-tagged antigens to magnetic beads covalently coupled with anti-His antibody. (b) Binding of patient plasma antibodies to antigen-coupled beads and detection by PE-labeled secondary antibodies (IgG, IgA or IgM) with the FlexMap 3D reader (Luminex). Median fuorescence intensity (MFI) proportional to bound secondary antibody is recorded. Figure created with BioRender.com. (c) Titration of anti-His capture antibody on magnetic beads. One of two independent experiments is depicted. (d-e) Optimization of antigen loading. (d) Reactivity of beads loaded with increasing doses of SARS-CoV-2 nucleoprotein (N) or SARS-CoV-2 spike protein subunit S1 (S1) with titered anti-N and anti-S1 mAbs and a SARS-CoV-2 positive patient plasma pool. One of three independent experiments is depicted. (e) Median fuorescence intensity (MFI) at 1/100 dilution and the 50 % efective concentration (EC50) values for anti-N and anti-S1 mAbs, the SARS-CoV-2 positive patient pool (+PP), two individual SARS-CoV-2 positive patient plasma (P1 and P2) and a plasma pool of pre-pandemic healthy donors (-PP). One of two independent experiments is depicted. (f) Final assessment of assay setup (5 µg anti-His Ab per million beads, 320 nM His-tagged antigens, Phycoerythrin (PE)-labeled secondary antibodies at 17500). Reactivity of the indicated SARS-CoV-2 antigens with serial dilutions of anti-N and anti-S mAbs, positive and negative donor plasma pools was probed. At least two independent experiments are depicted.

Supplementary Fig. 2. Assessment of assay variability. Titration of the positive control plasma donor pool composed of 20 SARS-CoV-2 RT-PCR positive patients. Median fluorescence intensity (MFI) for IgG, IgA and IgM reactivities to SARS-CoV-2 proteins (RBD, S1, S2, N) and empty bead reactivity of 31 independent titrations are shown.

Supplementary Fig. 3. Temporal stability and variability analysis. (a) Assessment of the temporal stability of antigen coupled beads. The SARS-CoV-2 positive plasma pool was titrated on 25 days and the distribution of all signal intensities (pooled over plasma dilutions and antigens) for each day depicted. (b) Histogram of the overall assay variability (coefficient of variation) for all tested Ig classes based on the variability of mean log10 MFI values from 31 independent titrations (7 dilution steps) of the positive control plasma pool depicted in Supplementary Fig. 2. (c-d) Boxplots depicting the overall assay variability stratifed by the four diferent antigens (c) and plasma dilutions (d) based on 31 independent titrations (7 dilution steps) of a positive plasma pool. (e) Boxplots showing the intraday variability stratifed by the four diferent antigens based on six independent titrations of a positive plasma pool performed on the same day. (f) Boxplots showing the intraday variability stratifed by the four diferent antigens based on a titration of a positive plasma pool performed on 10 diferent days. All boxplots represent the following: median with the middle line, upper and lower quartiles with the box limits, and 1.5x interquartile ranges with the whiskers.

Supplementary Fig. 4. Training cohort II – recent HCoV infection. Assessment of the multiplex SARS-CoV-2 ABCORA 5.0 on the pre-pandemic individuals with recent HCoV infection (training cohort II). Depicted are MFI signals normalized to empty bead controls (MFI-FOE). Grey boxes indicate values above the individually set MFI-FOE cut-ofs for SARS-CoV-2 specific responses for each antigen (see Supplementary Table 4). Each symbol and color corresponds to one HCoV (HKU1: N=17, OC43: N=27, NL63: N=22, 229E: N=9). Boxplots represent the following: median with the middle line, upper and lower quartiles with the box limits, and 1.5x interquartile ranges with the whiskers.

Supplementary Fig. 5. Interdependency of SARS-CoV-2 and HCoV HKU1 antibody reactivity. Spearman correlation matrix of SARS-CoV-2 (RBD, S1, S2, N) and HKU1 S1 antigen reactivity (based on logMFI-FOE) in (a) SARS-CoV-2 positive adults (N=389), (b) healthy, pre-pandemic adults (N=825), (c) pre-pandemic children (N=169) and (d) pre-pandemic samples from patients recently infected with a circulating HCoV strain (N=75). Non-signifcant correlations are left blank. Levels of significance are assessed by a two-sided test on the asymptotic t approximation of Spearman's rank correlation, and corrected by the Bonferroni method for multiple testing (p<0.05/420).

HKU1

b

Supplementary Fig. 6. Variable importance for computational models. (a) Correlation matrix of all immunoglobulin variables in SARS-CoV-2 positive patients from the training dataset (N=175). Defning fve clusters based on hierarchical clustering showed that IgA N and IgM N clustered separately from other IgA and IgM variables. Other variables (indicated by stars: all IgGs, IgAs without N and IgMs without N) were highly correlated. We therefore used the mean of these three clusters in the logistic regression. (b) Variable importance (measured as the mean decrease of node impurity with Gini index). Each of the 100 dots corresponds to a random forest performed on a bootstrap sample of the training dataset (N=823).

Supplementary Fig. 8. Association of binding and neutralization activity in early and late infection. (a) 50% Neutralization titers (NT50) titers against Wuhan-Hu-1 pseudotype in patients with known date of symptoms onset (N= 333). Patients were stratified according to time since first diagnosis to investigate early (less than 30 days post symptoms onset, lavender) and late (more than 30 days symptoms onset, turquoise) neutralization responses. Diference between these two groups was assessed with a linear mixed model with time since symptom onset (binary variable early/late) as fixed effect and individual as random effect and using a Satterthwaite approximation for a two-sided t-test on the parameter associated with time since symptom onset. (b) Linear regression analysis to defne association between neutralization (reciprocal NT50) and antibody binding (MFI-FOE). Black lines indicate linear regression predictions. Levels of signifcance are assessed by a two-sided test on the asymptotic t approximation of Spearman's rank correlation, and corrected by the Bonferroni method for multiple testing (p<0.05/1200, see Supplementary Fig. 9).

b

Early time points (<=30 days since positive RT-PCR, N=118)

Early time points (<=30 days since onset of symptoms, N=66)

Late time points (>30 days since onset of symptoms, N=267)

Supplementary Fig. 9. Correlation of antibody binding and neutralization activity in early and late infection. Spearman correlation matrix assessing agreement between SARS-CoV-2 antigen reactivity (RBD, S1, S2, N) based on logMFI-FOE values and neutralization (NT50, NT80, NT90) in SARS-CoV-2 positive adults (N= 389) divided in (a) early and (b) late time points corresponding to time since positive RT-PCR diagnosis (a, N=118 – b, N=251) or (c) early and (d) late corresponding to time since symptom onset (c, N=66 – d, N=267). Non-significant correlations are left blank. Levels of significance are assessed by a two-sided test on the asymptotic t approximation of Spearman's rank correlation, and corrected by the Bonferroni method for multiple testing (p<0.05/1200).

a barang na barang n

Supplementary Fig 10. Predicting neutralization capacity as a function of binding activity. Neutralization prediction based on a modified ULR-S1 model utilizing the diagnostic readout SOC instead of MFI-FOE values as input. Measured NT50 value versus sum of S1 SOC values (IgG, IgA, IgM) are depicted. Dashed lines correspond to a NT50=100 horizontally and the sum S1 SOCs=6 vertically. The sum S1 SOCs=6 corresponds to a specificity=84% and a sensitivity=80%. The grey shaded area corresponds to true positives (individuals with NT50 >100 predicted as neutralizers).

Supplementary Fig. 11. Monitoring temporal evolution of antibody responses (a) Heatmaps representing the measured MFI-FOE values and the outcome predicted with ABCORA 2.0 - 2.3 of measurements of SARS-CoV-2 positive patients with known dates of positive RT-PCR diagnosis (N=369) (upper panel) or with known dates of onset of symptoms (N=333) (lower panel). Purple and orange scales indicate days post positive RT-PCR or days post onset of symptoms, respectively, white-to-black scale indicates seroconversion predicted with the different ABCORA approaches. (b) Linear mixed model, with time since symptom onset as fixed effect and individual as random efect, estimating the decay of antibody binding activity based on ABCORA 2.0 measurements at 1-4 longitudinal time points in 120 individuals totaling in 251 measurements. Orange lines correspond to the models estimation and orange shaded areas to the 95% confdence intervals. Antibody half-lives (t1/2 in days) from signifcant models are depicted. Significance was assessed using Satterthwaite approximation for a two-sided t-test on the decay parameters. (c) Linear mixed model estimating the decay of neutralizing capacity in patients separated by their neutralizing activity. Only individuals with NT50>100 at their frst measurement were used to estimate the half-life. The black line corresponds to the model estimation and the grey shaded area to the 95% confdence interval. Signifcance was assessed using Satterthwaite approximation for a two-sided t-test on the slope parameters.

Supplementary Fig. 12. ABCORA 5 seroprofling records antibody reactivity to SARS-CoV-2 and four HCoVs. (a) Assessment of the multiplex SARS-CoV-2 ABCORA 5.0 on the indicated training (N= 825) and validation (N=635) cohorts (Supplementary Table 3). Depicted are MFI signals normalized to empty bead controls (MFI-FOE). Grey boxes indicate values above the individually set MFI-FOE cut-ofs for SARS-CoV-2 specifc responses for each antigen (see Supplementary Table 4). Boxplots represent the following: median with the middle line, upper and lower quartiles with the box limits, and 1.5x interquartile ranges with the whiskers. (b) Sensitivity and specificity of ABCORA 5 assay versions 5.0, 5.4 and 5.5 based on the combined training and validation cohort data depicted in (a) (see also Supplementary Table 11). False negative proportion (sensitivity; green) and false positive proportion (specificity; blue) samples are represented by the reduction from 100% (outer circle) per segment.

1 0.8 0.6 0.4 0.2 0 -0.2 -0.4 -0.6 -0.8 -1

SARS−CoV−2+ adults (III) + (VI) example and the strategy of the Healthy, pre-pandemic adults (I) + (IV)

Supplementary Fig. 13. Interdependencies between antibody reactivity to SARS-CoV-2 and the four HCoVs. Spearman correlation matrix assessing agreement between SARS-CoV-2 antigens (RBD, S1, S2, N) and HCoVs (229E, NL63, OC43, HKU1) (based on logMFI-FOE) in (a) SARS-CoV-2 positive adults (N= 389), (b) healthy, pre-pandemic adults (N= 825), (c) pre-pandemic children (N=169) and (d) pre-pandemic samples from patients recently infected with a circulating HCoV strain (N=75). Nonsignifcant correlations are left blank. Levels of signifcance are assessed by a two-sided test on the asymptotic t approximation of Spearman's rank correlation, and corrected by the Bonferroni method for multiple testing (p<0.05/1104).

Supplementary Fig. 14. Association between SARS-CoV-2 and HCoV antibody responses. Comparison of ABCORA 5.0 reactivity for SARS-CoV-2 and HCoVs in healthy, SARS-CoV-2 negative and SARS-CoV-2 infected individuals. Healthy donors were sampled in May 2020 (N=653; blue). Plasma from SARS-CoV-2 infected individuals were collected between April 2020 and February 2021 (N=389; red, Training III and Validation VI). Grey boxes indicate values above the individual MFI-FOE cut-ofs for SARS-CoV-2 specific responses for each antigen. Stars correspond to levels of significance of two-sided t-tests comparing negative versus positive patients. Levels of significance are corrected by the Bonferroni method for multiple testing and indicated as follows: *p<0.05/12, **p<0.01/12, ***p<0.001/12 (IgG HKU1: p=0.74, IgG OC43: p=0.75, IgG NL63: p=2.2x10-07, IgG 229E: p=2.3x10-05, IgA HKU1: p=1.9x10-04, IgA OC43: p=1.9x10-05, IgA NL63: p=2.6x10-11, IgA 229E: p=9.2x10-07, IgM HKU1: p=3.7x10-29, IgM OC43: p=1.5x10-06, IgM NL63: p=1.3x10-04, IgM 229E: p=4.9x10-03). Boxplots represent the following: median with the middle line, upper and lower quartiles with the box limits, and 1.5x interquartile ranges with the whiskers.

Supplementary Fig. 15. Impact of HCoV immunity on COVID-19 severity. Corresponding analysis to Fig. 8. Association of hospitalization status (not hospitalized (N=16); hospitalized not in ICU (N=42); hospitalized in ICU (N=22)) and HCoV antibody level. Infuence of HCoV reactivity (low/high) on the hospitalization status, as estimated with odds ratios, in an ordinal regression (with levels=not hospitalized (N=16); hospitalized not in ICU (N=42); hospitalized in ICU (N=22)) and a logistic regression (reference=not hospitalized (N=16); versus all hospitalized (N=64)). Multivariate analysis is adjusted on age, gender and time since positive RT-PCR. Data is presented as parameter estimation and its 95% confidence interval. Level of significance of the parameter is obtained with a two-sided t-test (p-value is displayed if <0.05, otherwise indicated as n.s.).

Suplementary Table 4. ABCORA 2.0 and 5.0 threshold and signal over cut-off settings for ranking individual antigen reactivities positive

FOE = fold over empty beads; FOE cut-offs as depicted in Fig. 1

 2 For IgG responses additional borderline cut-offs for N, RBD, and S1 were defined in order to register lower level reactivity.

 3 SOC = signal over cut-off. SOC values express individual measurements as FOE sample in relation to the respective FOE cut-off.

Supplementary Table 6. Median of sensitivity and specificity of ABCORA 2.3 approach in the 5-fold cross validation

